[Seite 54↓]

Literaturverzeichnis

[1]Schulze-Neick, I.; Uhlemann, F.; Nurnberg, J. H.; Bultmann, M.; Haas, N. A.; Dahnert, I.; Alexi-Meshkishvili, V.; Opitz, C.; Pappert, D.; Rossaint, R.; Kleber, F. X.; Hetzer, R. and Lange, P. E. (1997): [Aerosolized prostacyclin for preoperative evaluation and post- cardiosurgical treatment of patients with pulmonary hypertension], Z Kardiol 86 [2], pp. 71-80.

[2]Schulze-Neick, I.; Bultmann, M.; Werner, H.; Gamillscheg, A.; Vogel, M.; Berger, F.; Rossaint, R.; Hetzer, R. and Lange, P. E. (1997): Right ventricular function in patients treated with inhaled nitric oxide after cardiac surgery for congenital heart disease in newborns and children, Am J Cardiol 80 [3], pp. 360-3.

[3]Schulze-Neick, I.; Penny, D. J.; Rigby, M. L.; Morgan, C.; Kelleher, A.; Collins, P.; Li, J.; Bush, A.; Shinebourne, E. A. and Redington, A. N. (1999): L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery, Circulation 100 [7], pp. 749-55. URL: http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/referer?http://www.circulationaha.org/cgi/content/full/100/7/749

[4]Schulze-Neick, I.; Li, J.; Penny, D. J. and Redington, A. N. (2001): Pulmonary vascular resistance after cardiopulmonary bypass in infants: effect on postoperative recovery, J Thorac Cardiovasc Surg 121 [6], pp. 1033-9. URL: http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/referer?http://www.mosby.com/scripts/om.dll/serve%3faction=searchDB&searchDBfor=art&artType=abs&id=a113747&target=

[5]Schulze-Neick, I; Li, J; Reader, JA; Shekerdemian, L; Redington, AN and Penny, DJ (2001): The Endothelin Antagonist BQ123 Reduces Pulmonary Vascular

Resistance in Infants after Congenital Heart Surgery, J Thorac Cardiovasc Surg accepted.

[6]Schulze-Neick, I.; Werner, H.; Penny, D. J.; Alexi-Meskishvili, V. and Lange, P. E. (1999): Acute ventilatory restriction in children after weaning off inhaled nitric oxide: relation to rebound pulmonary hypertension, Intensive Care Med 25 [1], pp. 76-80.

[7]Schulze-Neick, I.; Penny, D. J.; Derrick, G. P.; Dhillon, R.; Rigby, M. L.; Kelleher, A.; Bush, A. and Redington, A. N. (2000): Pulmonary vascular-bronchial interactions: acute reduction in pulmonary blood flow alters lung mechanics, Heart 84 [3], pp. 284-9. URL: http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/referer?http://www.heartjnl.com/cgi/content/full/84/3/284

[8]Abrams, D.; Schulze-Neick, I. and Magee, A. G. (2000): Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension, Heart 84 [2], p. E4. URL: http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/referer?http://www.heartjnl.com/cgi/content/abstract/84/2/e4

[9]Schulze-Neick, I; Li, J; Petros, A and Redington, AN (2001): Intravenous Sildenafil (Viagra(r)) and Pulmonary Vascular Resistance in Children with Congenital Heart Disease, Eur Heart J 22 [Suppl], p. 76.

[10]Talner, C. N. (1998): Report of the New England Regional Infant Cardiac Program, by Donald C. Fyler, MD, Pediatrics, 1980;65(suppl):375-461, Pediatrics 102 [1 Pt 2], pp. 258-9. URL: http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/referer?http://www.pediatrics.org/cgi/content/full/102/1/258

[11]Ferencz, C.; Rubin, J. D.; McCarter, R. J.; Brenner, J. I.; Neill, C. A.; Perry, L. W.; Hepner, S. I. and Downing, J. W. (1985): Congenital heart disease: prevalence at livebirth. The Baltimore- Washington Infant Study, Am J Epidemiol 121 [1], pp. 31-6.

[12]MMWR (1998): Trends in infant mortality attributable to birth defects--United States, 1980-1995, MMWR Morb Mortal Wkly Rep 47 [37], pp. 773-8.

[13]Rich, S (1998): Executive summary from the World Syposium on Primary Pulmonary Hypertension, World Symposium on Primary Pulmonary Hypertension, Evian, France.

[14]Rabinovitch, M.; Bothwell, T.; Hayakawa, B. N.; Williams, W. G.; Trusler, G. A.; Rowe, R. D.; Olley, P. M. and Cutz, E. (1986): Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy, Lab Invest 55 [6], pp. 632-53.

[15]Christman, BW; McPherson, CD; Newman, JH; King, GA; Bernard, GR; Groves, BM and Loyd, JE (1992): An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension., NEJM 327 [2], pp. 70-5.

[16]Adatia, I; Barrow, SE; Stratton, PD; Miall-Allen, VM; Ritter, JM and Haworth, SG (1993): Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease., Circulation 88 [part I], pp. 2117-2122.

[17]Yeager, S. B.; Freed, M. D.; Keane, J. F.; Norwood, W. I. and Castaneda, A. R. (1984): Primary surgical closure of ventricular septal defect in the first year of life: results in 128 infants, J Am Coll Cardiol 3 [5], pp. 1269-76.

[18]Wagenvoort, C. A. (1985): Pathology of the pulmonary vasculature. Correlation with clinical and haemodynamic data, Schweiz Med Wochenschr 115 [39], pp. 1319-22.

[19]Heath, D. and Edwards, J.E. (1958): The pathology of hypertensive pulmonary vascular disease, Circulation 18 [10], pp. 533-547.

[20]Vogel, M ; Berger, F ; Kramer, A ; Alexi-Meshkishvili, V and Lange, PE (1999): Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects., Heart 82 [1], pp. 30-3.

[21]Haworth, SG (1983): Pulmonary vascular disease in secundum atrial septal defect in childhood, Am J Cardiol 51 [2], pp. 265-72.

[22]Cherian, G; Uthaman, CB; Durairaj, M; Sukumar, IP; Krishnaswami, S; Jairaj, PS; John, S; Krishnaswami, H and Bhaktaviziam, A (1983): Pulmonary hypertension in isolated secundum atrial septal defect: high frequency in young patients, Am Heart J 105 [6], pp. 952-7.

[23]Bull, C; Deanfield, J; de Leval, M; Stark, J; Taylor, JF and Macartney, FJ (1981): Correction of isolated secundum atrial septal defect in infancy, Arch Dis Child 56 [10], pp. 784-6. URL: C:\WINNT\Profiles\schulze-neick\Desktop\Entrez-PubMed.txt

[24]Haworth, SG; Sauer, U; Buhlmeyer, K and Reid, L (1977): Development of the pulmonary circulation in ventricular septal defect: a quantitative structural study, Am J Cardiol 40 [5], pp. 781-8.

[25]Newfeld, EA; Paul, MM; Muster, AJ and Idriss, FS (1974): Pulmonary vascular disease in complete transposition of the great arteries: a study of 200 patients., Am J Cardiol 34 [1], pp. 75-82.

[26]Collins-Nakai, R. L.; Rosenthal, A.; Castaneda, A. R.; Bernhard, W. F. and Nadas, A. S. (1977): Congenital mitral stenosis. A review of 20 years' experience, Circulation 56 [6], pp. 1039-47.

[27]Hammon, J. W., Jr.; Bender, H. W., Jr.; Graham, T. P., Jr.; Boucek, R. J., Jr.; Smith, C. W. and Erath, H. G., Jr. (1980): Total anomalous pulmonary venous connection in infancy. Ten years' experience including studies of postoperative ventricular function, J Thorac Cardiovasc Surg 80 [4], pp. 544-51.

[28]Friedli, B.; Kidd, B. S.; Mustard, W. T. and Keith, J. D. (1974): Ventricular septal defect with increased pulmonary vascular resistance. Late results of surgical closure, Am J Cardiol 33 [3], pp. 403-9.

[29]Hallidie-Smith, K. A.; Wilson, R. S.; Hart, A. and Zeidifard, E. (1977): Functional status of patients with large ventricular septal defect and pulmonary vascular disease 6 to 16 years after surgical closure of their defect in childhood, Br Heart J 39 [10], pp. 1093-101.

[30]Mattila, S; Merikallio, E and Tala, P (1979): ASD in patients over 40 years of age., Scand J Thorac Cardiovasc Surg 13 [1], pp. 21-4.

[31]Murphy, JG; Gersh, BJ; McGoon, MD; Mair, DD; Porter, CJ; Ilstrup, DM; McGoon, DC; Puga, FJ; Kirklin, JW and Danielson, GK (1990): Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years, N Engl J Med 323 [24], pp. 1645-50.

[32]Vongpatanasin, W; Brickner, ME; Hillis, LD and RA, Lange (1998): The Eisenmenger syndrome in adults., Ann Intern Med 128 [9], pp. 745-55.

[33]Olley, PM (1999): Congenital heart disease: six decades of progress., Semin Pediatr Neurol 6 [1], pp. 3-11.

[34]Lillehei, C. W.; Anderson, R. C. and Wang, Y. (1968): Clinical and hemodynamic changes after closure of ventricular septal defects, Jama 205 [12], pp. 822-7.

[35]Kouchoukos, N. T.; Blackstone, E. H. and Kirklin, J. W. (1978): Surgical implications of pulmonary hypertension in congenital heart disease, Adv Cardiol 22, pp. 225-31.

[36]Braunlin, E. A.; Moller, J. H.; Patton, C.; Lucas, R. V., Jr.; Lillehei, C. W. and Edwards, J. E. (1986): Predictive value of lung biopsy in ventricular septal defect: long-term follow-up, J Am Coll Cardiol 8 [5], pp. 1113-8.

[37]Haworth, S. G.; Radley-Smith, R. and Yacoub, M. (1987): Lung biopsy findings in transposition of the great arteries with ventricular septal defect: potentially reversible pulmonary vascular disease is not always synonymous with operability, J Am Coll Cardiol 9 [2], pp. 327-33.

[38]Wilson, N. J.; Seear, M. D.; Taylor, G. P.; LeBlanc, J. G. and Sandor, G. G. (1990): The clinical value and risks of lung biopsy in children with congenital heart disease, J Thorac Cardiovasc Surg 99 [3], pp. 460-8.

[39]Seear, M.; Wensley, D. and Werner, H. (1991): Comparison of three methods for measuring respiratory mechanics in ventilated children, Pediatr Pulmonol 10 [4], pp. 291-5.

[40]Vogel, J. H.; Grover, R. F.; Jamieson, G. and Blount, S. G., Jr. (1974): Long-term physiologic observations in patients with ventricular septal defect and increased pulmonary vascular resistance (with 2 color plates), Adv Cardiol 11 [00], pp. 108-22.

[41]Lock, J. E.; Einzig, S.; Bass, J. L. and Moller, J. H. (1982): The pulmonary vascular response to oxygen and its influence on operative results in children with ventricular septal defect, Pediatr Cardiol 3 [1], pp. 41-6.

[42]Bush, A; Busst, C; Booth, K; Knight, W.B. and Shinebourne, E.A. (1986): Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease?, Circulation 74 [1], pp. 135-44.

[43]Heath, D and Edwards, JE (1958): The pathology of hypertensive pulmonary vascular disease, Circulation 18 [533-47].

[44]Celermajer, D. S.; Cullen, S. and Deanfield, J. E. (1993): Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics, Circulation 87 [2], pp. 440-6.

[45]Nyhan, DP; Redmond, JM; Gillinov, AM; Nishiwaki, K and Murray, PA (1994): Prolonged pulmonary vascular hyperreactivity in conscious dogs after cardiopulmonary bypass, J Appl Physiol 77 [4], pp. 1584-1590.

[46]Dupuis, J.; Stewart, D. J.; Cernacek, P. and Gosselin, G. (1996): Human pulmonary circulation is an important site for both clearance and production of endothelin-1, Circulation 94 [7], pp. 1578-84.

[47]Ishikawa, S.; Miyauchi, T.; Sakai, S.; Ushinohama, H.; Sagawa, K.; Fusazaki, N.; Kado, H.; Sunagawa, H.; Honda, S.; Ueno, H. and et al. (1995): Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair, J Thorac Cardiovasc Surg 110 [1], pp. 271-3.

[48]Yoshibayashi, M.; Nishioka, K.; Nakao, K.; Saito, Y.; Matsumura, M.; Ueda, T.; Temma, S.; Shirakami, G.; Imura, H. and Mikawa, H. (1991): Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation, Circulation 84 [6], pp. 2280-5.

[49]Komai, H.; Adatia, I. T.; Elliott, M. J.; de Leval, M. R. and Haworth, S. G. (1993): Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease, J Thorac Cardiovasc Surg 106 [3], pp. 473-8.

[50]Petrossian, E.; Parry, A. J.; Reddy, V. M.; Akkersdijk, G. P.; McMullan, D. M.; Thompson, L.; Hendricks-Munoz, K. D.; Hallak, H.; Hanley, F. L. and Fineman, J. R. (1999): Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow, J Thorac Cardiovasc Surg 117 [2], pp. 314-23. URL: http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/referer?http://www1.mosby.com/mosbyscripts/mosby.dll%3faction=searchDB&searchDBfor=art&artType=abs&id=a94979&target=

http://www1.mosby.com/mosbyscripts/mosby.dll?action=searchDB&searchDBfor=art&artType=abs&id=a94979&target=

[51]Bando, K; Turrentine, MW; Sharp, MW; Sekine, Y; Aufiero, T; Sun, K; Sekine, E and Brown, JW (1996): Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management, J THrac Cardiovasc Surg 112, pp. 1600-9.

[52]Drummond, W. H.; Gregory, G. A.; Heymann, M. A. and Phibbs, R. A. (1981): The independent effects of hyperventilation, tolazoline, and dopamine on infants with persistent pulmonary hypertension, J Pediatr 98 [4], pp. 603-11.

[53]Ward, R. M.; Daniel, C. H.; Kendig, J. W. and Wood, M. A. (1986): Oliguria and tolazoline pharmacokinetics in the newborn, Pediatrics 77 [3], pp. 307-15.

[54]Bush, A.; Busst, C.; Knight, W.B. and Shinebourne, E.A. (1988): Comparison of the haemodynamic effects of epoprostenol (prostacyclin) and tolazolin, Br Heart J 60, pp. 141-8.

[55]Brook, M. M.; Fineman, J. R.; Bolinger, A. M.; Wong, A. F.; Heymann, M. A. and Soifer, S. J. (1994): Use of ATP-MgCl2 in the evaluation and treatment of children with pulmonary hypertension secondary to congenital heart defects, Circulation 90 [3], pp. 1287-93.

[56]Fineman, J. R.; Crowley, M. R. and Soifer, S. J. (1990): Selective pulmonary vasodilation with ATP-MgCl2 during pulmonary hypertension in lambs, J Appl Physiol 69 [5], pp. 1836-42.

[57]Frostell, C.; Fratacci, M.-D.; Wain, J. C.; Jones, R. and Zapol, W. M. (1991): Inhaled nitric oxide: A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction, Circulation 83, pp. 2038-2047.

[58]Gerlach, H; Rossaint, R; Pappert, D and Falke, KJ (1993): Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension patients with adult respiratory distress syndrome, Eur J Clin Invest 23, pp. 499-502.

[59]Rossaint, R.; Falke, K. J.; Lopez, F.; Slama, K.; Pison, U. and Zapol, W. M. (1993): Inhaled nitric oxide for the adult respiratory ditress syndrome, N Engl J Med 238, pp. 399-405.

[60]Booke, M; Bradford, DW; Hinder, F; Harper, D; Brauchle, RW; Traber, LD and Traber, DL (1996): Effects of inhaled nitric oxide and nebulized prostacyclin on hypoxic pulmonry vasoconstriciton in anesthetized sheep, Crit Care J 24, pp. 1841-48.

[61]Habler, E; Kleen, M; Takenaka, S; Leiderer, R; Pusch, R; Welte, M; Zwissler, B and Messmer, K (1995): Eight Hour's inhalation of prostacyclin aerosol in healthy lambs causes no signs of respiratory-tract tissue damage, Intensive Care Med 21 [Suppl 1], p. S52.

[62]Pappert, D; Busch, T; Gerlach, H; Lewandowski, K; Radermacher, P and Rossaint, R (1995): Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome, Anesthesiology 82, pp. 1507-11.

[63]Santak, B.; Schreiber, M; Kühn, P.; Lang, D. and Radermacher, P. (1995): Prostacyclin Aerosol in an Infant with Pulmonary Hypertension, Eur J Ped in press.

[64]Walmrath, D; Schneider, T; Pilch, J; Grimminger, F and Seeger, W (1993): Aerosolised prostacyclin in adult respiratory distress syndrome, Lancet 342 [Oct 16], pp. 961-962.

[65]Davies, NJH and Denison, DM (1979): The measurement of metabolic gas exchange by mass spectrometry alone, Respir Physiol 36, pp. 261-7.

[66]Shekerdemian, LS; Shore, DF; Lincoln, C; Bush, A and Redington, AN (1996): Negative-pressure ventilation improves cardiac output after right heart surgery, Circulation 94 [suppl II], pp. II-49-II-55.

[67]Fick, A (1870): Über die Messung des Blutquantums in den Herzventrikeln, SB-Phys-Med Ges Juli 9.

[68]Seear, M; Wensley, D and Werner, H (1991): Comparison of three methods for measuring respiratory mechanics in ventilated children, Pediatr Pulmonol 10, pp. 291-95.

[69]Lanteri, C J; Kano, S; Nicolai, T and Sly, P D (1995): Measurement of dynamic respiratory mechanics in neonatal and pediatric intensive care: The multiple linear regression technique, Pediatr Pulmonol 19, pp. 29-45.

[70]Rossaint, R; Kaisers, U and Schulze-Neick, I (1996): Effect of Nitric Oxide on Right Ventricular Function, Pinski, MR; Dhainaut, JF and Artigas, A, The pulmonary circulation: Moving from passive to active control pp. 147-156, Saunders, London Philadelphia Toronto.

[71]Wagner, F.; Dandel, M.; Gunther, G.; Loebe, M.; Schulze-Neick, I.; Laucke, U.; Kuhly, R.; Weng, Y. and Hetzer, R. (1997): Nitric oxide inhalation in the treatment of right ventricular dysfunction following left ventricular assist device implantation, Circulation 96 [9 Suppl], pp. II-291-6.

[72]Girard, C.; Durand, P. G.; Vedrinne, C.; Pannetier, J. C.; Falke, K. and Adnot, S. (1993): Inhaled nitric oxide for right ventricular failure after heart transplantation, J Cardiothorac Vasc Anaesth 7, pp. 481-485.

[73]Kieler-Jensen, N; Ricksten, SE; Stenqvist, O; Bergh, CH; Lindelov, B; Wennmalm, A; Waagstein, F and Lundin, S (1994): Inhaled nitric oxide in the evaluation of heart transplantation candidates with elevated pulmonary vascular resistance, J Heart Lung Transplant 13, pp. 366-75.

[74]Lindberg, L.; Sjöberg, T.; Ingemansson, R. and Steen, S. (1996): Inhalation of nitric oxide after lung transplantation, Ann Thorac Surg 61, pp. 956-962.

[75]Miller, O. I.; Tang, S. F.; Keech, A.; Pigott, N. B.; Beller, E. and Celermajer, D. S. (2000): Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study, Lancet 356 [9240], pp. 1464-9.

[76]Haas, N. A.; Schulze-Neick, I. and Lange, P. E. (1995): Intratracheal prostacyclin for resuscitation in primary pulmonary hypertension, Lancet 346 [8975], p. 643.

[77]Mehta, S.; Short, K.; Schwartz, D.; Nelson, D.; Levy, M.; Hill, N. S.; Simms, H. and Klinger, J. R. (1996): A controlled trial of inhaled nitric oxide in patients with the acute repiratory distress syndrome (ARDS) [abstract], Am J Respir Crit Care Med 153, p. A591.

[78]Dellinger, R. P.; Zimmermann, J. L.; Hyers, T. M.; Taylor, R. W.; Straube, R. L.; Harber, D. L.; Damasc, M. C.; Davis Jr., K. and Crimer, G. J. (1996): Inhaled nitric oxide in ARDS; preliminary results of a multicenter clinical trial [abstract], Cri care Med 24(Suppl), p. A29.

[79]Barberà, J. A.; Roger, N.; Roca, J.; Rovira, I.; Higenbottam, T. and Rodriguez-Roisin, R. (1996): Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease, Lancet 347, pp. 436-440.

[80]The Neonatal Inhaled Nitric Oxide Study Group (1997): Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure, New Engl J Med 336, pp. 597-604.

[81]Miller, O. I.; Tang, S. F.; Keech, A. and Celermmajer, D. S. (1995): Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide, Lancet 346[letter], pp. 51-52.

[82]Petros, A.J. (1994): Down-regulation of endogenous nitric oxide production after prolonged administration., Lancet 344, p. 191.

[83]Atz, A. M.; Adatia, I. and Wessel, D. L. (1996): Rebound pulmonary hypertension after inhalation of nitric oxide, Ann Thorac Surg 62, pp. 1759-1764.

[84]Beghetti, M; Habre, W; Friedli, B and Berner, M (1995): Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients., Br Heart J 73, pp. 65-68.

[85]Olschewski, H.; Ghofrani, H. A.; Walmrath, D.; Schermuly, R.; Temmesfeld-Wollbruck, B.; Grimminger, F. and Seeger, W. (1999): Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis, Am J Respir Crit Care Med 160 [2], pp. 600-7. URL: http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/referer?http://www.ajrccm.org/cgi/content/full/160/2/600

[86]Petkov, V.; Ziesche, R.; Mosgoeller, W.; Schenk, P.; Vonbank, K.; Stiebellehner, L.; Raderer, M.; Brunner, C.; Kneussl, M. and Block, L. H. (2001): Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment, Thorax 56 [9], pp. 734-6. URL: http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/referer?http://www.thoraxjnl.com/cgi/content/abstract/56/9/734

[87]Hoeper, M. M.; Olschewski, H.; Ghofrani, H. A.; Wilkens, H.; Winkler, J.; Borst, M. M.; Niedermeyer, J.; Fabel, H. and Seeger, W. (2000): A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group, J Am Coll Cardiol 35 [1], pp. 176-82.

[88]Higenbottam, T. and Siddons, T. (2001): Trials of inhaled iloprost and other new vasodilating prostaglandins, Eur Respir J 17 [1], pp. 6-7.

[89]Gorenflo, M.; Zheng, C.; Werle, E.; Fiehn, W. and Ulmer, H. E. (2001): Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension, J Cardiovasc Pharmacol 37 [4], pp. 489-92.

[90]Williams, D. B.; Kiernan, P. D.; Metke, M. P.; Marsh, H. M. and Danielson, G. K. (1984): Hemodynamic response to positive end-expiratory pressure following right atrium-pulmonary artery bypass (Fontan procedure), J Thorac Cardiovasc Surg 87 [6], pp. 856-61.

[91]Fiebore, L.; Brunet, F.; Dhainaut, J. F.; Monchi, M.; Belghith, M. and Dinh-Xuan, A. T. (1995): Effect of inhaled nitric oxide on right ventricular function in adult respiratory distress syndrome, Am J Respir Crit Care Med 151, pp. 1414-1419.

[92]Rossaint, R; Slama, K; Steudel, W; Gerlach, H.; Pappert, D; Veit, S and Falke, K (1995): Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome, Intensive Care Med 21, pp. 197-203.

[93]Borst, H G; Berlund, E; Whittenberger, J L; Mead, J; McGregor, M and Collier, C (1957): The effect of pulmonary vascular pressures on the mechanical properties of the lungs of anesthetized dogs, J Clin Invest 36, pp. 1708-14.

[94]Wildhaber, J. H.; Uhlig, T. and Sly, P. D. (1998): Partitioning of alterations in pulmonary mechanics due to vascular engorgement in piglets, Pediatr Pulmonol 25 [1], pp. 45-51.

[95]Griffin, AJ; Ferrara, JD; Lax, JO and Cassels, DE (1972): Pulmonary compliance: and index of cardiovascular status in infancy, Am J Dis Child 123, p. 89.

[96]Colebatch, HJ; Berend, N and Maccioni, FJ (1992): Effect of the chest wall and blood volume on pulmonary distensibility, J Appl Physiol 72 [1], pp. 186-93.

[97]Schindler, M. B.; Bohn, D. J.; Bryan, A. C.; Cutz, E. and Rabinovitch, M. (1995): Increased respiratory system resistance and bronchial smooth muscle hypertrophy in children with acute postoperative pulmonary hypertension, Am J Respir Crit Care Med 152 [4 Pt 1], pp. 1347-52.

[98]Snapper, JR; Hutchison, AA; Ogletree, ML and Brigham, KL (1991): Effects of cyclooxygenase inhibitors on the alterations in lung mechanics caused by endotoxemia in the unanesthetized sheep, J Clin Invest 72, pp. 63-76.

[99]Wheeler, AP; Jesmok, G and Brigham, KL (1990): Tumor necrosis factor's effects on lung mechanics, gas exchange, and airway reactivity in sheep, J Appl Physiol 68 [6], pp. 2542-9.

[100]Gamillscheg, A.; Zobel, G.; Urlesberger, B.; Berger, J.; Dacar, D.; Stein, J. I.; Rigler, B.; Metzler, H. and Beitzke, A. (1997): Inhaled nitric oxide in patients with critical pulmonary perfusion after Fontan-type procedures and bidirectional Glenn anastomosis, J Thorac Cardiovasc Surg 113 [3], pp. 435-42.

[101]Hickey, P. R.; Hansen, D. D.; Wessel, D. L.; Lang, P.; Jonas, R. A. and Elixson, E. M. (1985): Blunting of stress responses in the pulmonary circulation of infants by fentanyl, Anesth Analg 64 [12], pp. 1137-42.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
19.07.2005